Full-Time

Senior Clinical Trial Associate

Updated on 7/23/2026

Dyne Therapeutics

Dyne Therapeutics

201-500 employees

Develops muscle-disease therapies using FORCE platform

Compensation Overview

$86k - $105k/yr

Waltham, MA, USA

In Person

On-site in Waltham, MA; occasional travel for meetings.

Category
Biology & Biotech (1)
Required Skills
biostatistics

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in life sciences, healthcare, or a related field preferred; equivalent combination of education and relevant experience may be considered
  • 3+ years of relevant hands-on clinical operations or drug development experience, preferably in a Sponsor setting and with exposure to global or multi-site clinical trials
  • Working knowledge of clinical trial operations, ICH-GCP guidelines, regulatory requirements, TMF expectations, and inspection readiness principles
  • Experience collaborating across multiple functional areas, such as Clinical Operations, Clinical Development, Regulatory Affairs, Quality Assurance, Data Management, Biostatistics, Medical Writing, Clinical Supply, Finance, and external vendors
  • Proficiency with clinical trial tracking systems, document management tools, Microsoft Office applications, and other systems used to support clinical trial execution and documentation
  • Demonstrated ability to work independently, collaborate effectively within cross-functional teams, manage competing priorities, and deliver accurate, high-quality work with strong follow-through
  • High level of professionalism, discretion, integrity, accountability, and alignment with Dyne’s values and commitment to patients
  • Willingness to travel for job-related activities, including investigator meetings, site visits, conferences, or vendor meetings, if required (expected travel for this position is ~5%)
Responsibilities
  • Support the Clinical Study Lead and cross-functional study team across all phases of global clinical trial execution, including feasibility, study planning, start-up, enrollment, maintenance, and closeout activities
  • Partner with the Clinical Study Lead to facilitate effective communication across internal study teams, CROs, vendors, and other external partners, helping to proactively identify risks, resolve issues, and keep study activities on track
  • Track study metrics, operational milestones, site activation progress, enrollment trends, vendor deliverables, and Sponsor oversight activities; work closely with CROs and vendors to ensure tracking tools are accurate, complete, and current
  • Support the review, coordination, and quality control of essential study documents, including informed consent forms, site initiation visit materials, essential regulatory documents, study plans, recruitment materials, manuals, trackers, and other trial-related documents to ensure consistency, accuracy, and compliance
  • Assist with the development, routing, distribution, and maintenance of Sponsor study documents and operational materials, such as protocols, protocol amendments, administrative letters, pharmacy manuals, study reference materials, and team communications
  • Attend internal study team meetings and external CRO/vendor meetings; prepare and maintain agendas, meeting materials, minutes, decision logs, and action item trackers to support accountability and timely follow-through
  • Coordinate logistics and materials for investigator meetings, principal investigator calls, site-facing communications, conferences, vendor meetings, and other study-related forums
  • Collect, file, reconcile, and track essential documents for the trial master file (TMF); conduct routine TMF reviews, identify gaps, follow up on missing documentation, and support ongoing inspection readiness activities
  • Take initiative to improve Clinical Operations processes by identifying opportunities for standardization, efficiency, quality, and continuous improvement within study teams and across the department
  • Maintain and update study tracking tools, dashboards, contact lists, document logs, training records, and other operational resources to support transparency and timely decision-making
  • Use sound judgment, intellectual curiosity, and a continuous improvement mindset to identify practical solutions, improve ways of working, and support consistent execution across study teams
  • Communicate clearly and professionally with internal and external stakeholders, build effective working relationships, escalate issues appropriately, and follow through on commitments with urgency and attention to quality

Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2017

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Preclinical data shows sustained dystrophin expression and muscle function improvement after single low dose[1].
  • ACHIEVE trial shows dose-dependent splicing correction and functional improvement in DM1 patients[3].
  • Dyne secured $400M debt facility to support US launches of DMD and DM1 therapies within two years[3]

What critics are saying

  • Sarepta's upadacersen dominates DMD market with 80% adoption, blocking Dyne's switch opportunities in 12–18 months
  • FDA rejection risk for accelerated approval due to inadequate Phase 1/2 data persists in 6–12 months
  • Dyne faces insolvency within 12 months if FDA denies approval due to $200M debt and equity dilution

What makes Dyne Therapeutics unique

  • Dyne's FORCE™ platform targets TfR-1 for precise oligonucleotide delivery to muscle and CNS[1][2].
  • Dyne pioneers low-dose, infrequent therapy for DM1 using FORCE™ platform validation[4][6].
  • Dyne advances clinical programs for DMD and DM1 with fast track and orphan drug designations[3].

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

0%

2 year growth

-3%
Dyne Therapeutics
Dec 10th, 2025
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock | Dyne Therapeutics, Inc.

(Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.